Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Reports Decreased Q3 Revenues, Widened Losses

NEW YORK, Nov. 4 (GenomeWeb News) - Incyte today reported significantly decreased third-quarter revenues, and widened net losses.

 

The Palo Alto, Calif., company reported revenues of $13.2 million for the third quarter, compared to $22.4 million for the same period last year. Net loss widened to $43.0 million, from $38.4 million for the third quarter of 2002.

 

R&D expenses were down to $28.6 million, from $47.4 million in the third quarter of 2002.

 

As of Sept. 30, Incyte had $315.1 million in cash and cash equivalents.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.